These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22344547)

  • 41. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
    Sajadi MM; Lewis GK; Seaman MS; Guan Y; Redfield RR; DeVico AL
    J Virol; 2012 May; 86(9):5014-25. PubMed ID: 22379105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity.
    Lopalco L; Pastori C; Cosma A; Burastero SE; Capiluppi B; Boeri E; Beretta A; Lazzarin A; Siccardi AG
    AIDS Res Hum Retroviruses; 2000 Jan; 16(2):109-15. PubMed ID: 10659050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.
    Serwanga J; Ssemwanga D; Muganga M; Nakiboneka R; Nakubulwa S; Kiwuwa-Muyingo S; Morris L; Redd AD; Quinn TC; Kaleebu P;
    Vaccine; 2018 Jan; 36(4):578-586. PubMed ID: 29274699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
    González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
    PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
    Hraber P; Seaman MS; Bailer RT; Mascola JR; Montefiori DC; Korber BT
    AIDS; 2014 Jan; 28(2):163-9. PubMed ID: 24361678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variables influencing anti-human immunodeficiency virus type 1 neutralizing human monoclonal antibody (NhMAb) production among infected Thais.
    Akapirat S; Avihingsanon A; Ananworanich J; Schuetz A; Ramasoota P; Luplertlop N; Ono K; Ikuta K; Utachee P; Kameoka M; Leaungwutiwong P
    Southeast Asian J Trop Med Public Health; 2013 Sep; 44(5):825-41. PubMed ID: 24437318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
    Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
    PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.
    Ferreira CB; Merino-Mansilla A; Llano A; Pérez I; Crespo I; Llinas L; Garcia F; Gatell JM; Yuste E; Sanchez-Merino V
    J Virol; 2013 Nov; 87(22):12227-36. PubMed ID: 24006439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.
    Cornelissen M; Euler Z; van den Kerkhof TL; van Gils MJ; Boeser-Nunnink BD; Kootstra NA; Zorgdrager F; Schuitemaker H; Prins JM; Sanders RW; van der Kuyl AC
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1135-1142. PubMed ID: 26910384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease.
    Douvas A; Takehana Y; Ehresmann G; Chernyovskiy T; Daar ES
    AIDS Res Hum Retroviruses; 1996 Nov; 12(16):1509-17. PubMed ID: 8911576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
    Simek MD; Rida W; Priddy FH; Pung P; Carrow E; Laufer DS; Lehrman JK; Boaz M; Tarragona-Fiol T; Miiro G; Birungi J; Pozniak A; McPhee DA; Manigart O; Karita E; Inwoley A; Jaoko W; Dehovitz J; Bekker LG; Pitisuttithum P; Paris R; Walker LM; Poignard P; Wrin T; Fast PE; Burton DR; Koff WC
    J Virol; 2009 Jul; 83(14):7337-48. PubMed ID: 19439467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor.
    Sun Y; Qiao Y; Zhu Y; Chong H; He Y
    Oncotarget; 2017 Sep; 8(38):63047-63063. PubMed ID: 28968970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression.
    Warren RQ; Wong MT; Melcher GP; Blatt SP; Zapiola I; Bouzas MB; Muchinik G; Anderson SA; Kennedy RC
    Clin Diagn Lab Immunol; 1995 Jul; 2(4):400-3. PubMed ID: 7583913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections.
    Fenyö EM; Putkonen P
    Immunol Lett; 1996 Jun; 51(1-2):95-9. PubMed ID: 8811351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.
    Tremblay M; Wainberg MA
    J Infect Dis; 1990 Sep; 162(3):735-7. PubMed ID: 2387997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.
    Rouers A; Klingler J; Su B; Samri A; Laumond G; Even S; Avettand-Fenoel V; Richetta C; Paul N; Boufassa F; Hocqueloux L; Mouquet H; Rouzioux C; Lambotte O; Autran B; Graff-Dubois S; Moog C; Moris A;
    EBioMedicine; 2017 Jul; 21():158-169. PubMed ID: 28615147
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multivariate analysis of human immunodeficiency virus type 1 neutralization data.
    Nyambi PN; Nkengasong J; Lewi P; Andries K; Janssens W; Fransen K; Heyndrickx L; Piot P; van der Groen G
    J Virol; 1996 Sep; 70(9):6235-43. PubMed ID: 8709250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.